KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00432-012-1319-7PMID 23015072PMCID PMC11824176
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC).

  2012cited by this paper
• Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.

  2012cited by this paper
• Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.

  2012cited by this paper
• Evaluation of Individual Codon 12 and 13 Mutant (MT) KRAS Alleles as Prognostic and Predictive Biomarkers of Response to Panitumumab (pmab) in Patients with Metastatic Colorectal Cancer (mCRC)

  2011cited by this paper
• The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma

  2010cited by this paper
• Molecular characterization of commonly used cell lines for bone tumor research: A trans‐European EuroBoNet effort

  2010cited by this paper
• Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

  2010cited by this paper
• Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery

  2010cited by this paper
• Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

  2010cited by this paper
• Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

  2010cited by this paper
• Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

  2010cited by this paper
• Clinical Relevance of KRAS in Human Cancers

  2010cited by this paper
• Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

  2009cited by this paper
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  2009cited by this paper
• Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

  2009cited by this paper
• PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

  2008cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression

  2007cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007cited by this paper
• Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer.

  2007cited by this paper
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• Recurrent KRAS codon 146 mutations in human colorectal cancer

  2006cited by this paper
• Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  2006cited by this paper
• Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue.

  2006cited by this paper
• Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray

  2006cited by this paper
• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  2005cited by this paper
• Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues

  2004cited by this paper
• Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.

  2003cited by this paper
• Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.

  2001cited by this paper
• Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

  2001cited by this paper
• K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.

  2000cited by this paper
• Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis.

  1993cited by this paper
• ras genes.

  1987cited by this paper

• Calendula officinalis as a source of KRAS-targeted anticancer agents: a comprehensive computational assessment

  2025cites this paper
• RAS‐targeted cancer therapy: Advances in drugging specific mutations

  2023cites this paper
• Combination of photoacoustic and fluorescence in-vivo imaging using bioavailable nanoparticles containing a fluorescent dye

  2023cites this paper
• The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.

  2021cites this paper
• Mutation-specific and common phosphotyrosine signatures of KRAS G12D and G13D alleles.

  2020cites this paper
• Study of Ras Mutations’ Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis

  2020cites this paper
• Clinicopathological and molecular features of colorectal cancer with synchronous adenoma

  2020cites this paper
• Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D

  2019cites this paper
• Isoform-Specific Destabilization of the Active Site Reveals Molecular Mechanism of Intrinsic Activation of KRas G13D

  2019cites this paper
• Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis

  2019cites this paper
• Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer

  2018cites this paper
• Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer

  2017cites this paper
• Mutation spectra of RAS gene family in colorectal cancer.

  2016cites this paper
• Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.

  2016cites this paper
• Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

  2016cites this paper
• RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer.

  2016cites this paper
• Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection

  2016cites this paper
• Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality.

  2016cites this paper
• KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.

  2015cites this paper
• PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.

  2015cites this paper
• Methylation of EGFR by Arginine Methyltransferase PRMT1 Enhances EGFR Signaling and Cetuximab resistance

  2015cites this paper
• KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.

  2015cites this paper
• Select biomarkers for tumors of the gastrointestinal tract: present and future.

  2015cites this paper
• Differences in sensitivity to EGFR inhibitors could be explained by described biochemical differences between oncogenic Ras mutants

  2014influential citation
• Tumor Heterogeneity Revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA Intratumor Mutation Profile Differences and Their Therapeutic Implications

  2014cites this paper
• Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review

  2014cites this paper
• Panitumumab (Vectibix®): A Treatment for Metastatic Colorectal Cancer

  2014cites this paper
• c-MET and KRAS: Signalling and Clinical Implications in Colorectal Cancer

  2014cites this paper
• KRAS status and resistance to epidermal growth factor receptor tyrosine‐kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta‐analysis

  2014cites this paper
• Impact of genetic profiles on the efficacy of anti-EGFR antibodies in metastatic colorectal cancer with KRAS mutation.

  2014cites this paper
• KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

  2014cites this paper
• Clinical relevance of KRAS mutations in codon 13: Where are we?

  2014cites this paper
• Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations

  2013cites this paper
• The heterogeneity of KRAS mutations in colorectal cancer and its biomarker implications: an ever-evolving story

  2013cites this paper